At this AEI event, panelists will discuss the practical potential and wisdom of further changes to patent law designed to promote innovation and entrepreneurial vigor in the United States.

The U.S. Patent and Trademark Office has resisted researchers' overreaching in their patenting of genes, and researchers' work is seldom compromised by patents.

Congress should act in protecting patents for follow-on biologics, relying on a few basic principles that do not suppress research and developmentin this vital sector.

A recent court decision has been widely applauded as a pathway to abolishing human gene patents. But a closer look shows that getting rid of gene patents would probably be a big mistake.

The controversial Patent Reform Act would be costly and counterproductive.

The U.S. patent system is more important than ever. It is also a mess, but help may finally be on the way.

Permitting slightly higher drug prices today will guarantee incentives for innovation and development tomorrow.

Satisfying the needs of politicians inside the World Health Organization is not going to fight AIDS infection.